111 Capital Makes New Investment in Halozyme Therapeutics, Inc. $HALO

111 Capital purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, HoldingsChannel.com reports. The fund purchased 13,238 shares of the biopharmaceutical company’s stock, valued at approximately $689,000.

A number of other large investors have also recently made changes to their positions in HALO. Isthmus Partners LLC lifted its position in Halozyme Therapeutics by 2.5% during the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after purchasing an additional 169 shares during the period. OneDigital Investment Advisors LLC raised its stake in Halozyme Therapeutics by 1.7% during the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 175 shares during the last quarter. Park Place Capital Corp lifted its holdings in shares of Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 182 shares during the period. Xponance Inc. boosted its stake in shares of Halozyme Therapeutics by 1.1% in the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 198 shares during the last quarter. Finally, Bessemer Group Inc. increased its position in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 207 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Down 3.8%

HALO opened at $68.98 on Friday. The company has a market capitalization of $8.07 billion, a PE ratio of 15.78, a price-to-earnings-growth ratio of 0.38 and a beta of 1.16. The firm has a 50-day simple moving average of $70.45 and a two-hundred day simple moving average of $61.95. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same period in the previous year, the business earned $0.91 earnings per share. The firm’s revenue for the quarter was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at $55,285,726.65. This represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Nicole Labrosse sold 20,000 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the transaction, the chief financial officer owned 24,306 shares of the company’s stock, valued at $1,840,207.26. This trade represents a 45.14% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 128,227 shares of company stock worth $8,908,195. 2.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on HALO. JMP Securities raised their target price on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a “market outperform” rating in a research report on Wednesday, August 6th. JPMorgan Chase & Co. raised their price objective on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a “neutral” rating in a report on Thursday, August 7th. Benchmark upped their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an “overweight” rating in a research report on Monday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus target price of $70.44.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.